Please ensure Javascript is enabled for purposes of website accessibility

How Is Fulgent Genetics Staying Ahead of Its Competition?

By Keith Speights and Brian Orelli, PhD – Nov 20, 2021 at 6:05AM

Key Points

  • Fulgent Genetics is attempting to scale up but faces significant competition.
  • The company is trying to become the go-to genetic testing provider for doctors.
  • Fulgent is also acquiring companies in adjacent markets.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The key is by focusing on doctors.

Fulgent Genetics (FLGT 4.42%) ranks as one of the fastest-growing genetic testing companies around. But the company faces plenty of rivals. In this Motley Fool Live video recorded on Nov. 10, Motley Fool contributors Keith Speights and Brian Orelli answer a viewer's question about how Fulgent can stay ahead of the competition.

10 stocks we like better than Fulgent Genetics, Inc.
When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

They just revealed what they believe are the ten best stocks for investors to buy right now... and Fulgent Genetics, Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of November 10, 2021

 

Keith Speights: Brad says he's really enjoying the conversation and discussion of results this morning. "How do you view Fulgent Genetics' earnings as they continue to scale and pivot going forward in the near term with so much competition?"

Brian Orelli: I think that they're really trying to become the go-to for doctors. I think that's the reason why they went and used the cash that they're generating from COVID-19, and went out and bought companies that are adjacent to genetic testing, so they would do like tissue staining testing on tumors.

This way, the doctors can send their tissue samples to Fulgent and they can do a whole bunch of different tests and the doctor can order them all from one place. That makes life much easier. I think that's the way Fulgent's trying to compete.

As you rightly point out, there's a lot of companies that are developing genetic testing. Then they're trying to make things as easy as possible and as efficient as possible. I think that's also a step in the right direction for doctors in their offices.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Fulgent Genetics, Inc. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.